Relapses of sarcoidosis: What are they and can we predict who will get them?

European Respiratory Journal

Volumn 43, Issue 2, 2014, Pages 337-339

  Baughman, Robert P ^a   Judson, Marc A ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b Albany Medical Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; SARCOIDOSIS;

EID: 84893493649     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00138913     Document Type: Review

References (39)

1. Cottin V, Müller-Quernheim J. Sarcoidosis from bench to bedside: a state-of-the-art series for the clinician. Eur Respir J 2012; 40: 14-16.
2. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins hospital. Medicine (Baltimore) 1999; 78: 65-111.
3. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149: 893-898.
4. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631.
5. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 52-58.
6. Panselinas E, Judson MA. Acute pulmonary exacerbations of sarcoidosis. Chest 2012; 142: 827-836.
7. Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 56-64.
8. McKinzie BP, Bullington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339: 1-4.
9. Zappala CJ, Desai SR, Copley SJ, et al. Optimal scoring of serial change on chest radiography in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 130-138.
10. Nunes H, Uzunhan Y, Gille T, et al. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur Respir J 2012; 40: 750-765.
11. Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41: 1424-1438.
12. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
13. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006; 99: 307-315.
14. Rodrigues SC, Rocha NA, Lima MS, et al. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 34-43.
15. Grunewald J, Eklund A. Löfgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009; 179: 307-312.
16. Veltkamp M, Van Moorsel CH, Rijkers GT, et al. Genetic variation in the Toll-like receptor gene cluster (TLR10- TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens 2012; 79: 25-32.
17. Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet 2013; 50: 290-297.
18. Pabst S, Fränken T, Schönau J, et al. Transforming growth factor-b gene polymorphisms in different phenotypes of sarcoidosis. Eur Respir J 2011; 38: 169-175.
19. Baughman RP, Ploysongsang Y, Roberts RD, et al. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis 1983; 128: 631-633.
20. Köhn H, Klech H, Mostbeck A, et al. 67Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood T-lymphocytes. Eur J Nucl Med 1982; 7: 413-416.
21. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med 2010; 31: 409-418.
22. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802.
23. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196.
24. Stagaki E, Mountford WK, Lackland DT, et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135: 468-476.
25. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 2011; 33: 901-913.
26. Markatseli TE, Alamanos Y, Saougou I, et al. Survival of TNF-a antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol 2012; 30: 31-38.
27. Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009; 14: 522-528.
28. Baughman RP, Lower EE, Ingledue R, et al. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29: 26-33.
29. van der Maas A, Kievit W, van den Bemt BJ, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012; 71: 1849-1854.
30. Vorselaars ADM, Verwoerd A, van Moorsel CHM, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43: 602-609.
31. Rothkrantz-Kos S, Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49: 1510-1517.
32. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-a release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-1592.
33. Bargagli E, Bianchi N, Margollicci M, et al. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest 2008; 68: 479-483.
34. Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010; 137: 1391-1397.
35. Mostard RL, Van Kuijk SM, Verschakelen JA, et al. A predictive tool for an effective use of 18F-FDG PET in assessing activity of sarcoidosis. BMC Pulm Med 2012; 12: 57.
36. Keijsers RG, van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2013; 41: 743-751.
37. Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 123-129.
38. Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and 18F-FDG PET activity in sarcoidosis. Respir Med 2013; 107: 439-447.
39. Keijsers RG, Verzijlbergen JF, van Diepen DM, et al. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 143-149.